FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 44 filers reported holding FATE THERAPEUTICS INC in Q3 2015. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2016 | $908,000 | +83.4% | 291,067 | 0.0% | 0.10% | +45.6% |
| Q2 2016 | $495,000 | -3.9% | 291,067 | +1.8% | 0.07% | -2.9% |
| Q1 2016 | $515,000 | -47.5% | 285,953 | -1.8% | 0.07% | -61.7% |
| Q4 2015 | $981,000 | -36.8% | 291,067 | 0.0% | 0.18% | -53.1% |
| Q3 2015 | $1,551,000 | -17.6% | 291,067 | 0.0% | 0.39% | -52.7% |
| Q2 2015 | $1,883,000 | +32.3% | 291,067 | 0.0% | 0.82% | -41.4% |
| Q1 2015 | $1,423,000 | -2.8% | 291,067 | 0.0% | 1.40% | +237.7% |
| Q4 2014 | $1,464,000 | -1.3% | 291,067 | +0.0% | 0.42% | -45.2% |
| Q3 2014 | $1,484,000 | -19.6% | 291,000 | -0.5% | 0.76% | -56.4% |
| Q2 2014 | $1,846,000 | -37.6% | 292,567 | -3.6% | 1.74% | +54.9% |
| Q1 2014 | $2,956,000 | +55.1% | 303,538 | 0.0% | 1.12% | -5.9% |
| Q4 2013 | $1,906,000 | – | 303,538 | – | 1.19% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 3,379,064 | $131,006,000 | 24.77% |
| Redmile Group, LLC | 12,957,222 | $502,351,000 | 15.68% |
| Grosvenor Holdings, L.L.C. | 1,037,256 | $40,214,000 | 7.85% |
| Casdin Capital, LLC | 3,400,000 | $131,818,000 | 5.91% |
| Ally Bridge Group (NY) LLC | 181,500 | $7,037,000 | 5.22% |
| DAFNA Capital Management LLC | 500,930 | $19,421,000 | 5.06% |
| Deep Track Capital, LP | 2,000,000 | $77,540,000 | 4.97% |
| Artal Group S.A. | 2,000,000 | $77,540,000 | 3.25% |
| Tri Locum Partners LP | 190,345 | $7,380,000 | 2.88% |
| ARK Investment Management | 10,988,182 | $426,012,000 | 1.78% |